AnX Robotica
Private Company
Total funding raised: $44M
Overview
AnX Robotica is an innovative private company pioneering AI-enhanced capsule endoscopy for gastrointestinal diagnostics. Its core platform, NaviCam®, includes systems for the small bowel, esophagus, and whole-gut transit testing, augmented by its proprietary ProScan™ AI software which dramatically reduces image reading time. The company is commercial-stage, with its lead product already FDA-cleared and in clinical use, targeting the large and growing market for efficient, non-invasive GI diagnostic solutions. AnX Robotica represents a convergence of medical device engineering and digital health AI, aiming to improve workflow efficiency and diagnostic accuracy for physicians.
Technology Platform
Integrated capsule endoscopy hardware (for small bowel, esophagus, motility) combined with proprietary AI software (ProScan™) for automated image analysis and diagnostic assistance.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
AnX competes in the capsule endoscopy market against large incumbents like Medtronic (Given Imaging) and Olympus, who have broader product portfolios and extensive sales forces. Its key differentiator is its FDA-cleared ProScan™ AI, though competitors are actively developing similar AI capabilities. In motility, it would compete against older diagnostic standards and other emerging technologies.